PURPOSE: The goal of this study was to develop an immunodeficient rat model of retinal degeneration (RD nude rats) that will not reject transplanted human cells. METHODS: SD-Tg(S334ter)3Lav females homozygous for a mutated mouse rhodopsin transgene were mated with NTac:NIH-Whn (NIH nude) males homozygous for the Foxn1 (rnu) allele. Through selective breeding, a new stock, SD-Foxn1 Tg(S334ter)3Lav (RD nude) was generated such that all animals were homozygous for the Foxn1 (rnu) allele and either homo- or hemizygous for the S334ter transgene. PCR-based assays for both the Foxn1 (rnu) mutation and the S334ter transgene were developed for accurate genotyping. Immunodeficiency was tested by transplanting sheets of hESC-derived neural progenitor cells to the subretinal space of RD nude rats, and, as a control, NIH nude rats. Rats were killed between 8 and 184 days after surgery, and eye sections were analyzed for human, neuronal, and glial markers. RESULTS: After transplantation to RD nude and to NIH nude rats, hESC-derived neural progenitor cells differentiated to neuronal and glial cells, and migrated extensively from the transplant sheets throughout the host retina. Migration was more extensive in RD nude than in NIH nude rats. Already 8 days after transplantation, donor neuronal processes were found in the host inner plexiform layer. In addition, host glial cells extended processes into the transplants. The host retina showed the same photoreceptor degeneration pattern as in the immunocompetent SD-Tg(S334ter)3Lav rats. Recipients survived well after surgery. CONCLUSIONS: This new rat model is useful for testing the effect of human cell transplantation on the restoration of vision without interference of immunosuppression.
PURPOSE: The goal of this study was to develop an immunodeficientrat model of retinal degeneration (RD nude rats) that will not reject transplanted human cells. METHODS:SD-Tg(S334ter)3Lav females homozygous for a mutated mouserhodopsin transgene were mated with NTac:NIH-Whn (NIH nude) males homozygous for the Foxn1 (rnu) allele. Through selective breeding, a new stock, SD-Foxn1 Tg(S334ter)3Lav (RD nude) was generated such that all animals were homozygous for the Foxn1 (rnu) allele and either homo- or hemizygous for the S334ter transgene. PCR-based assays for both the Foxn1 (rnu) mutation and the S334ter transgene were developed for accurate genotyping. Immunodeficiency was tested by transplanting sheets of hESC-derived neural progenitor cells to the subretinal space of RD nude rats, and, as a control, NIH nude rats. Rats were killed between 8 and 184 days after surgery, and eye sections were analyzed for human, neuronal, and glial markers. RESULTS: After transplantation to RD nude and to NIH nude rats, hESC-derived neural progenitor cells differentiated to neuronal and glial cells, and migrated extensively from the transplant sheets throughout the host retina. Migration was more extensive in RD nude than in NIH nude rats. Already 8 days after transplantation, donor neuronal processes were found in the host inner plexiform layer. In addition, host glial cells extended processes into the transplants. The host retina showed the same photoreceptor degeneration pattern as in the immunocompetent SD-Tg(S334ter)3Lav rats. Recipients survived well after surgery. CONCLUSIONS: This new rat model is useful for testing the effect of human cell transplantation on the restoration of vision without interference of immunosuppression.
Authors: D Trifunović; A Sahaboglu; J Kaur; S Mencl; E Zrenner; M Ueffing; B Arango-Gonzalez; F Paquet-Durand Journal: Curr Mol Med Date: 2012-06 Impact factor: 2.222
Authors: Steven D Schwartz; Jean-Pierre Hubschman; Gad Heilwell; Valentina Franco-Cardenas; Carolyn K Pan; Rosaleen M Ostrick; Edmund Mickunas; Roger Gay; Irina Klimanskaya; Robert Lanza Journal: Lancet Date: 2012-01-24 Impact factor: 79.321
Authors: Jason S Meyer; Sara E Howden; Kyle A Wallace; Amelia D Verhoeven; Lynda S Wright; Elizabeth E Capowski; Isabel Pinilla; Jessica M Martin; Shulan Tian; Ron Stewart; Bikash Pattnaik; James A Thomson; David M Gamm Journal: Stem Cells Date: 2011-08 Impact factor: 6.277
Authors: M Joseph Phillips; Kyle A Wallace; Sarah J Dickerson; Michael J Miller; Amelia D Verhoeven; Jessica M Martin; Lynda S Wright; Wei Shen; Elizabeth E Capowski; E Ferda Percin; Enio T Perez; Xiufeng Zhong; Maria V Canto-Soler; David M Gamm Journal: Invest Ophthalmol Vis Sci Date: 2012-04-18 Impact factor: 4.799
Authors: Igor Nasonkin; Vasiliki Mahairaki; Leyan Xu; Glen Hatfield; Brian J Cummings; Charles Eberhart; David K Ryugo; Dragan Maric; Eli Bar; Vassilis E Koliatsos Journal: Stem Cells Date: 2009-10 Impact factor: 6.277
Authors: Dustin Hambright; Kye-Yoon Park; Matthew Brooks; Ron McKay; Anand Swaroop; Igor O Nasonkin Journal: Mol Vis Date: 2012-04-12 Impact factor: 2.367
Authors: Mandeep S Singh; Peter Charbel Issa; Rachel Butler; Chris Martin; Daniel M Lipinski; Sumathi Sekaran; Alun R Barnard; Robert E MacLaren Journal: Proc Natl Acad Sci U S A Date: 2013-01-03 Impact factor: 11.205
Authors: Andrzej T Foik; Georgina A Lean; Leo R Scholl; Bryce T McLelland; Anuradha Mathur; Robert B Aramant; Magdalene J Seiler; David C Lyon Journal: J Neurosci Date: 2018-11-05 Impact factor: 6.167
Authors: Biju B Thomas; Danhong Zhu; Tai-Chi Lin; Young Chang Kim; Magdalene J Seiler; Juan Carlos Martinez-Camarillo; Bin Lin; Yousuf Shad; David R Hinton; Mark S Humayun Journal: Graefes Arch Clin Exp Ophthalmol Date: 2018-09-13 Impact factor: 3.117
Authors: Matthew M LaVail; Shimpei Nishikawa; Roy H Steinberg; Muna I Naash; Jacque L Duncan; Nikolaus Trautmann; Michael T Matthes; Douglas Yasumura; Cathy Lau-Villacorta; Jeannie Chen; Ward M Peterson; Haidong Yang; John G Flannery Journal: Exp Eye Res Date: 2017-11-06 Impact factor: 3.467
Authors: Tai-Chi Lin; Magdalene J Seiler; Danhong Zhu; Paulo Falabella; David R Hinton; Dennis O Clegg; Mark S Humayun; Biju B Thomas Journal: Stem Cells Int Date: 2017-08-27 Impact factor: 5.443
Authors: Ratnesh K Singh; Paige Winkler; Francois Binette; Randolph D Glickman; Magdalene Seiler; Simon M Petersen-Jones; Igor O Nasonkin Journal: J Tissue Eng Regen Med Date: 2020-01-06 Impact factor: 3.963
Authors: Ratnesh K Singh; Francois Binette; Magdalene Seiler; Simon M Petersen-Jones; Igor O Nasonkin Journal: J Ocul Pharmacol Ther Date: 2020-10-14 Impact factor: 2.671